+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Influenza Vaccine Market - Global Forecast 2026-2032- Product Image
Influenza Vaccine Market - Global Forecast 2026-2032- Product Image
New

Influenza Vaccine Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 191 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5012972
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The influenza vaccine market is undergoing a pivotal transformation as new technologies, operational challenges, and evolving procurement practices reshape both competitive dynamics and public health objectives. Senior leaders must navigate this shifting landscape to ensure effective risk management and sustained organizational value.

Market Snapshot: Influenza Vaccine Market Size and Growth

The Influenza Vaccine Market expanded from USD 9.41 billion in 2025 to USD 10.28 billion in 2026 and is forecast to reach USD 17.94 billion by 2032, reflecting a CAGR of 9.65%. This trajectory is propelled by ongoing platform innovation, the introduction of enhanced presentation types, and an increasing demand for seasonal as well as pandemic immunization programs. With growing attention to supply chain resilience, regulatory evolution, and diverse regional and stakeholder imperatives, market participants face significant opportunities coupled with operational and strategic complexities.

Scope & Segmentation

  • Vaccine Types: Inactivated, live attenuated, and recombinant—all presenting distinct manufacturing timelines, storage needs, and communication challenges.
  • Age Groups: Adult, geriatric, and pediatric segments, each requiring specific formulations and approaches to outreach, dosing, and risk management.
  • Dosage Formats: Multi-dose and single-dose options impact inventory strategy, distribution costs, and efforts to reduce wastage.
  • Presentation Formats: Prefilled syringes in glass or plastic, and vials in various sizes influence workflow efficiency, safety perceptions, and waste processing protocols.
  • Distribution Channels: Direct sales and hospital pharmacies shape contract terms, supply chain visibility, and logistics coordination.
  • End Users: Clinics—outpatient and specialty—and hospitals in both public and private sectors, each with varying procurement cycles, budgetary limits, and cold chain capabilities.
  • Geographic Regions: Americas; Europe, Middle East & Africa; Asia-Pacific, highlighting regional discrepancies in regulatory requirements, infrastructure development, and program priorities affecting access, pricing, and supply strategies.
  • Platform Technologies: Adoption of recombinant and cell-based methods, adjuvant improvements, and fill-finish solutions enables flexibility and rapid response to fluctuating market pressures.

Key Takeaways: Strategic Insights for Decision-Makers

  • Innovation in antigen design and advanced production platforms equips manufacturers to swiftly accommodate shifting strain coverage needs and newly identified public health threats.
  • Ensuring supply chain robustness is increasingly prioritized; organizations are adopting diversified sourcing and nearshoring to fortify resilience and streamline logistics management.
  • Emerging presentation formats—such as glass and plastic prefilled syringes—facilitate faster vaccine administration and address evolving clinical and operational standards.
  • Enhanced data-driven immunization planning, reinforced by advanced surveillance, supports proactive deployment and greater adaptability in public health responses.
  • Subtle market segmentation differences across age groups, dose forms, and sales channels necessitate highly tailored commercial strategies for optimal engagement in diverse settings.
  • Region-specific differences in infrastructure, regulatory systems, and procurement models call for custom approaches to market supply, stakeholder engagement, and long-term growth alignment.

Tariff Impact: How U.S. Measures Are Shaping Supply Chains

New U.S. tariff policies on imported vaccine components and packaging are altering economic models and risk profiles throughout the supply chain. Vaccine manufacturers now face increased material costs, prompting a reevaluation of supplier contracts, consideration of nearshoring, and tactical sourcing adjustments to safeguard operational continuity. These changes affect both single-dose and multi-dose products, necessitating more extensive inventory control and potentially longer lead times. Adjustments in sourcing and production may require additional regulatory validation, introducing further complexity to capacity and product portfolio management.

Methodology & Data Sources

This report integrates structured primary interviews with systematic secondary research. Key sources include regulatory filings, peer-reviewed studies, procurement guidelines, and industry best practices. Validation incorporated insights from immunization program leads, procurement officers, and manufacturing experts to ensure operational relevance.

Why This Report Matters

  • Empowers strategic planning by presenting timely, actionable market and supply chain trends for the influenza vaccine segment.
  • Facilitates risk management and procurement optimization, especially amid evolving regulatory, supply chain, and tariff challenges.
  • Clarifies technical distinctions and regional priorities supporting targeted resource allocation and product development.

Conclusion

Effective coordination across product development, supply, and procurement is crucial for success in the evolving influenza vaccine market. Organizations that respond proactively to technological, regulatory, and operational change will be best positioned for sustained impact and growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Influenza Vaccine Market, by Vaccine Type
8.1. Inactivated
8.2. Live Attenuated
8.3. Recombinant
9. Influenza Vaccine Market, by Age Group
9.1. Adult
9.2. Geriatric
9.3. Pediatric
10. Influenza Vaccine Market, by Dosage
10.1. Multi Dose
10.2. Single Dose
11. Influenza Vaccine Market, by Presentation
11.1. Prefilled Syringe
11.1.1. Glass Prefilled Syringe
11.1.2. Plastic Prefilled Syringe
11.2. Vial
11.2.1. Multi Dose Vial
11.2.2. Single Dose Vial
12. Influenza Vaccine Market, by Distribution Channel
12.1. Direct Sales
12.2. Hospital Pharmacies
13. Influenza Vaccine Market, by End User
13.1. Clinics
13.1.1. Outpatient Clinics
13.1.2. Specialty Clinics
13.2. Hospitals
13.2.1. Private Hospitals
13.2.2. Public Hospitals
14. Influenza Vaccine Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Influenza Vaccine Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Influenza Vaccine Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Influenza Vaccine Market
18. China Influenza Vaccine Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AstraZeneca plc
19.6. Changchun BCH Bioengineering Co., Ltd.
19.7. China National Pharmaceutical Group Co., Ltd.
19.8. CSL Limited
19.9. GlaxoSmithKline plc
19.10. Pfizer Inc.
19.11. Sanofi S.A.
19.12. Serum Institute of India Private Limited
19.13. Sinovac Biotech Ltd.
19.14. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
List of Figures
FIGURE 1. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 123. EUROPE INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. EUROPE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 125. EUROPE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 126. EUROPE INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 127. EUROPE INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 128. EUROPE INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 129. EUROPE INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 130. EUROPE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. EUROPE INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. EUROPE INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 133. EUROPE INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 145. AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 147. AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 148. AFRICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 149. AFRICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 150. AFRICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 151. AFRICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 152. AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. AFRICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. AFRICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 155. AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 168. ASEAN INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. ASEAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 170. ASEAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 171. ASEAN INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 172. ASEAN INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 173. ASEAN INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 174. ASEAN INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 175. ASEAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. ASEAN INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. ASEAN INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 178. ASEAN INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 179. GCC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. GCC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 181. GCC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 182. GCC INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 183. GCC INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 184. GCC INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 185. GCC INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 186. GCC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 187. GCC INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. GCC INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 189. GCC INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 201. BRICS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. BRICS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 203. BRICS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 204. BRICS INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 205. BRICS INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 206. BRICS INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 207. BRICS INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 208. BRICS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. BRICS INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. BRICS INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 211. BRICS INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 212. G7 INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 213. G7 INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 214. G7 INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 215. G7 INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 216. G7 INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 217. G7 INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 218. G7 INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 219. G7 INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 220. G7 INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. G7 INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 222. G7 INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 223. NATO INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 224. NATO INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 225. NATO INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 226. NATO INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 227. NATO INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 228. NATO INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 229. NATO INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 230. NATO INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 231. NATO INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 232. NATO INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 233. NATO INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 234. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 238. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 239. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 240. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 241. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 242. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 243. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 246. CHINA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 247. CHINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 248. CHINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 249. CHINA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 250. CHINA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
TABLE 251. CHINA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
TABLE 252. CHINA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 253. CHINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 254. CHINA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 255. CHINA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 256. CHINA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Influenza Vaccine market report include:
  • AstraZeneca plc
  • Changchun BCH Bioengineering Co., Ltd.
  • China National Pharmaceutical Group Co., Ltd.
  • CSL Limited
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Private Limited
  • Sinovac Biotech Ltd.
  • Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages191
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 10.28 Billion
Forecasted Market Value ( USD ) by 2032 $ 17.94 Billion
Compound Annual Growth Rate9.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Influenza Vaccines Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Influenza Vaccines Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Influenza Vaccines Market Report 2025 - Product Image

Influenza Vaccines Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Influenza Vaccine Market Size, Share, and Trends by Vaccine Type, Technology, Age Group, Route of Administration, Region, and Forecast 2025-2033 - Product Image

Influenza Vaccine Market Size, Share, and Trends by Vaccine Type, Technology, Age Group, Route of Administration, Region, and Forecast 2025-2033

  • Report
  • 136 Pages
  • Global
From
Avian Influenza Vaccine Market - Global Strategic Business Report - Product Image

Avian Influenza Vaccine Market - Global Strategic Business Report

  • Report
  • 286 Pages
  • Global
From
Avian Influenza Vaccines Market - Global Forecast 2026-2032 - Product Image

Avian Influenza Vaccines Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From

About the Flu Vaccine Market

The Flu Vaccine market is a subset of the larger Vaccines market, which is composed of products designed to prevent and treat infectious diseases. Flu Vaccines are specifically designed to protect against influenza, a highly contagious virus that can cause severe illness and even death. Flu Vaccines are typically administered annually, and are recommended for people of all ages, including pregnant women and those with chronic health conditions. Flu Vaccines are typically developed by pharmaceutical companies, and are then approved and distributed by government health agencies. In addition to traditional flu vaccines, there are also recombinant vaccines, which are produced using genetic engineering techniques. Companies in the Flu Vaccine market include Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.